Our mission is to deliver solutions and bring hope to as many people as possible.
Biosimilar medicines enable us to do so, by ensuring access to treatments and contributing to the sustainability of healthcare systems worldwide.
More info
The imminent wave of biosimilars in oncology
(Extracted from ESMO Open Cancer Horizon, September 20181)
Since 2001, 59 biosimilars have been submitted for approval in Europe, of which 39 (25 different molecules) have been approved and marketed. In 2017 alone, 14 biosimilars [...]
+
mAbxience, sponsor of BIOSPAIN 2018
BIOSPAIN, the largest biotech event organized by a national bioindustry association in Europe (ASEBIO), and one of the largest in the world by the number of one-to-one [...]
+
Our business model is B2B (business to business), which allows us to market our products worldwide through our consolidated network of local partners, all leaders in their markets.
+